TIDMSTX TIDMSTXW

RNS Number : 2719G

Shield Therapeutics PLC

04 August 2016

Shield Therapeutics plc

("Shield" or the "Company")

Result of Annual General Meeting

London, UK, 04 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.

- Ends -

For further information please contact:

 
 Shield Therapeutics plc                +44 (0)191 511 8507 
 Carl Sterritt, Chief Executive 
  Officer 
  Richard Jones, Chief Financial 
  Officer 
 
 NOMAD 
  Liberum Capital Limited 
  Christopher Britton 
  Steve Pearce 
  Jamil Miah                            +44 (0)20 3100 2222 
 Financial PR Advisor                   +44 (0)203 709 5700 
  Consilium Strategic Communications     shieldtherapeutics@consilium-comms.com 
 Mary-Jane Elliott 
  Matthew Neal 
  Lindsey Neville 
  Hendrik Thys

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has an approved product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGAKQDKKBKDBFK

(END) Dow Jones Newswires

August 04, 2016 06:05 ET (10:05 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Shield Therapeutics Charts.
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Shield Therapeutics Charts.